Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Current Assets (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Current Assets for 4 consecutive years, with $18.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 79.93% year-over-year to $18.4 million, compared with a TTM value of $18.4 million through Sep 2025, down 79.93%, and an annual FY2024 reading of $64.9 million, down 36.3% over the prior year.
  • Current Assets was $18.4 million for Q3 2025 at Atara Biotherapeutics, down from $24.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $347.0 million in Q2 2022 and bottomed at $18.4 million in Q3 2025.
  • Average Current Assets over 4 years is $150.2 million, with a median of $106.4 million recorded in 2024.
  • The sharpest move saw Current Assets decreased 22.61% in 2024, then crashed 79.93% in 2025.
  • Year by year, Current Assets stood at $295.1 million in 2022, then plummeted by 65.48% to $101.9 million in 2023, then tumbled by 36.3% to $64.9 million in 2024, then tumbled by 71.6% to $18.4 million in 2025.
  • Business Quant data shows Current Assets for ATRA at $18.4 million in Q3 2025, $24.8 million in Q2 2025, and $27.2 million in Q1 2025.